{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:42:50Z","timestamp":1787164970444,"version":"build-2736575974"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K17919"],"award-info":[{"award-number":["19K17919"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,4,5]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying antirheumatic drugs were randomly divided into two groups at baseline, and tofacitinib treatment in combination with MTX was administered to both groups. Either MTX or tofacitinib was then withdrawn if patients achieved Clinical Disease Activity Index remission at week 52. The primary outcome was the proportion of patients who sustained clinical remission at week 104.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 113 patients participated in this study. Among them, a total of 48 patients achieved remission at week 52. After discontinuation of tofacitinib, only 29.2% (7\/24) of patients remained remission, while 50.0% (10\/20) of patients, which was numerically higher but not statistically significant, sustained remission after MTX discontinuation. A greater proportion of bio-na\u00efve patients achieved remission at week 52 and sustained low disease activity with tofacitinib discontinuation at week 104. Additionally, the patients who were able to discontinue tofacitinib without flares had lower rheumatoid factor (p=0.04) and lower anti-cyclic citrullinated peptide antibody (p=0.051) before discontinuation of tofacitinib. No severe adverse events were recorded after discontinuation of tofacitinib or MTX. In patients who relapsed after tofacitinib discontinuation, 71.4% achieved remission with resumption of tofacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study implies that a blanket cessation of tofacitinib may not be suitable for all patients, given that 58% of the participants experienced relapse. However, the withdrawal of tofacitinib is unlikely to result in the acquisition of treatment-resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003029","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T11:39:55Z","timestamp":1682422795000},"page":"e003029","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-9263","authenticated-orcid":false,"given":"Satoshi","family":"Kubo","sequence":"first","affiliation":[{"name":"Department of Molecular Targeted Therapies, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"},{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-3881","authenticated-orcid":false,"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Matsui","sequence":"additional","affiliation":[{"name":"Division of Allergology and Rheumatology, Department of Diabetes Endocrinology and Clinical Immunology, Hyogo Medical University, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshino","family":"Inoue","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Ogura","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-9435","authenticated-orcid":false,"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"2025090313374902000_9.2.e003029.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025090313374902000_9.2.e003029.2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"2025090313374902000_9.2.e003029.3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-Term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"2025090313374902000_9.2.e003029.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11232"},{"key":"2025090313374902000_9.2.e003029.5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/art.40780","article-title":"Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis","volume":"71","author":"van Vollenhoven","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313374902000_9.2.e003029.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025090313374902000_9.2.e003029.7","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313374902000_9.2.e003029.8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313374902000_9.2.e003029.9","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"key":"2025090313374902000_9.2.e003029.10","unstructured":"FDA approves boxed warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). 2019. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and"},{"key":"2025090313374902000_9.2.e003029.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025090313374902000_9.2.e003029.12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/14397595.2020.1741870","article-title":"Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders","volume":"31","author":"Nakano","year":"2021","journal-title":"Modern Rheumatology"},{"key":"2025090313374902000_9.2.e003029.13","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1093\/rheumatology\/keac075","article-title":"Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study","volume":"61","author":"Tanaka","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313374902000_9.2.e003029.14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/rheumatology\/kex068","article-title":"Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study","volume":"56","author":"Kubo","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313374902000_9.2.e003029.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025090313374902000_9.2.e003029.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025090313374902000_9.2.e003029.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2025090313374902000_9.2.e003029.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"2025090313374902000_9.2.e003029.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.149765"},{"key":"2025090313374902000_9.2.e003029.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.20712"},{"key":"2025090313374902000_9.2.e003029.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204016"},{"key":"2025090313374902000_9.2.e003029.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121491"},{"key":"2025090313374902000_9.2.e003029.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200379"},{"key":"2025090313374902000_9.2.e003029.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61751-1"},{"key":"2025090313374902000_9.2.e003029.25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (preserve): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"The Lancet"},{"key":"2025090313374902000_9.2.e003029.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025090313374902000_9.2.e003029.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213271"},{"key":"2025090313374902000_9.2.e003029.28","first-page":"S22","article-title":"Discontinuation of biologics in patients with rheumatoid arthritis","volume":"31","author":"Tanaka","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313374902000_9.2.e003029.29","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313374902000_9.2.e003029.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204761"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:38:09Z","timestamp":1756931889000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,25]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/rmdopen-2023-003029"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003029","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}